Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with idiopathic epiretinal membrane~* Preoperative visual acuity of snellen equivalent 20/32 or worse~Exclusion Criteria:~* History or presence of any of the following:~* uveitis~* macular hole~* previous vitreoretinal surgery~* any other retinal pathology that could affect anatomic or functional results~* Age Related Macular Degeneration~* Diabetic Retinopathy~* Diabetic Macular Edema~* Retinal Vein Occlusion~* Pre-existing Macular Disease

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PPV + MP + DEX (Type: EXPERIMENTAL): Patients will undergo pars plana vitrectomy, membrane peel, and concomitant Ozurdex implant (0.7 mg dose).
- PPV + MP (Type: ACTIVE_COMPARATOR): Patients will undergo pars plana vitrectomy with membrane peel, without Ozurdex implant.

Based on this trial design, predict the completion outcome and termination type (if applicable).